GRCL Stock Price History and Quote Analysis: Insights for Investors
Gracell Biotechnologies Inc.
Stock Price Today
Gracell Biotechnologies Inc. (GRCL) stock surged +0.05%, trading at $10.25 on NASDAQ, up from the previous close of $10.25. The stock opened at $10.26, fluctuating between $10.17 and $10.28 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
Company Information
| Employees | 314 |
| Beta | -0.345 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Gracell Biotechnologies Inc. (NASDAQ: GRCL) stock price is $10.25 in the last trading session. During the trading session, GRCL stock reached the peak price of $10.28 while $10.17 was the lowest point it dropped to. The percentage change in GRCL stock occurred in the recent session was 0.05% while the dollar amount for the price change in GRCL stock was $0.01.
The NASDAQ listed GRCL is part of Biotechnology industry that operates in the broader Healthcare sector. Gracell Biotechnologies Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Yajin Ni M.D., Ph.D.
Chief Technology Officer
Dr. Wei Cao
Founder, Chairman & Chief Executive Officer
Dr. Wendy Li M.D.
Chief Medical Officer
Ms. Erin Li
Executive Officer
Dr. Samuel Suhua Zhang M.B.A., Ph.D.
Chief Bus. Officer
Dr. Jenny Ni M.D., Ph.D.
Chief Technology Officer
Dr. Yili Xie M.B.A., Ph.D.
Chief Financial Officer
Dr. Wei Cao BM, Ph.D.
Founder, Chairman & Chief Executive Officer
GRCL's closing price is 632.14% higher than its 52-week low of $1.40 where as its distance from 52-week high of $10.44 is -1.77%.
Number of GRCL employees currently stands at 314.
Official Website of GRCL is: https://www.gracellbio.com
GRCL could be contacted at phone 865 126 2626701 and can also be accessed through its website. GRCL operates from Building 12, Block B, Suzhou, 215123, China.
GRCL stock volume for the day was 6.37M shares. The average number of GRCL shares traded daily for last 3 months was 1.46M.
The market value of GRCL currently stands at $989.87M with its latest stock price at $10.25 and 96.57M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com